This content is machine translated MACE risk, heart failure incidence and all-cause mortality Metabolic syndrome as a cardiovascular risk factor Current data from 2025/2026 show: 1.54 billion adults worldwide are affected – and the risk of serious cardiovascular events increases in proportion to the number of components. New evidence on...…
View Post 10 min This content is machine translated Mechanisms, evidence and therapeutic consequences GLP-1 receptor agonists in cardiology GLP-1 receptor agonists (GLP-1RAs) have rapidly evolved from antidiabetic drugs to cardiometabolic therapies with clinically proven reductions in hard cardiovascular endpoints – and increasingly beyond the traditional diabetes population. The...…
View Post 2 min This content is machine translated Hyperthyroidism Thyroid surgery reduces the risk of cardiovascular events Thyroid surgery is associated with a lower long-term risk of major adverse cardiovascular events (MACE) in patients with hyperthyroidism compared to thyroid medications, according to study results published in JAMA…
View Post 6 min This content is machine translated Type 2 diabetes Better quality of life thanks to modern diabetes therapy The cardiovascular benefit of SGLT2 inhibitors and GLP1 analogues is now considered established, and non-diabetics may also benefit. For optimal results, therapy should be tailored to individual patient characteristics.
